Lista de obras -

Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) ⬇️

artículo científico publicado el 1 de octubre de 2003

African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology

artículo científico publicado en 2002

Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial.

artículo científico publicado en 2006

Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.

artículo científico publicado en 2005

Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice

artículo científico publicado en 2005

Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment

artículo científico publicado en 2005

Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials

artículo científico publicado en 2007

Atrial fibrillation and mortality in African American patients with heart failure: Results from the African American Heart Failure Trial (A-HeFT) ⬇️

artículo científico publicado el 1 de julio de 2011

Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.

artículo científico publicado en 2013

Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study

artículo científico publicado en 2007

Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial.

artículo científico publicado en 2006

C-reactive protein in heart failure: prognostic value and the effect of valsartan

artículo científico publicado en 2005

Calculated plasma volume status and prognosis in chronic heart failure.

artículo científico publicado en 2014

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

artículo científico publicado en 2003

Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T

artículo científico publicado en 2020

Clinical and analytical considerations in the study of health status in device trials for heart failure

artículo científico publicado en 2005

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

artículo científico publicado en 2013

Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.

artículo científico publicado en 2007

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

artículo científico publicado en 2004

Contributors

Definition, classification, and staging of the adult cardiomyopathies: a proposal for revision.

artículo científico publicado en 2004

Determinants of radial artery pulse wave analysis in asymptomatic individuals

artículo científico publicado en 2004

Digoxin Use and Heart Failure Outcomes: Results from the Valsartan Heart Failure Trial (Val‐HeFT) ⬇️

artículo científico publicado el 1 de septiembre de 2010

Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data

artículo científico publicado en 2006

EARTH: Endothelin A Receptor Antagonist Trial in Heart Failure

Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial

artículo científico publicado en 2007

Early cardiovascular structural and functional abnormalities as a guide to future morbid events

artículo científico publicado en 2020

Effect of Fixed-Dose Combined Isosorbide Dinitrate/Hydralazine in Elderly Patients in the African-American Heart Failure Trial ⬇️

artículo científico publicado el 1 de agosto de 2012

Effect of Valsartan on hospitalization: results from Val-HeFT.

artículo científico publicado en 2003

Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.

artículo científico publicado en 2008

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

artículo científico publicado en 1991

Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial

artículo científico

Effect of nebivolol or atenolol vs. placebo on cardiovascular health in subjects with borderline blood pressure: the EVIDENCE study.

artículo científico publicado en 2017

Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.

artículo científico publicado en 2004

Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial

artículo científico publicado en 2005

Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial

artículo científico publicado en 2007

Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure

artículo científico publicado en 2002

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).

artículo científico publicado en 2002

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

artículo científico publicado en 2002

Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT).

artículo científico publicado en 2010

Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial

artículo científico publicado en 2008

Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial

artículo científico publicado en 2008

From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report

artículo científico publicado en 2006

G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.

artículo científico publicado en 2014

Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.

artículo científico

Heart Failure With Recovered Ejection Fraction in African Americans: Results From the African-American Heart Failure Trial.

artículo científico publicado en 2017

High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure

scientific article published on 26 October 2018

Identifying early cardiovascular disease to target candidates for treatment

artículo científico publicado en 2008

Incremental prognostic value of changes in B-type natriuretic peptide in heart failure

artículo científico publicado en 2006

Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial

artículo científico publicado en 2006

Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study

artículo científico publicado en 2013

Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.

artículo científico publicado en 2007

Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox

artículo científico publicado en 2007

Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial

artículo científico publicado en 2004

Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials

artículo científico publicado en 2015

Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).

artículo científico publicado en 2004

Nitric oxide's role in heart failure: pathophysiology and treatment. Introduction

artículo científico publicado en 2003

Nuggets, pearls, and vignettes of master heart failure clinicians. Part 4--treatment

artículo científico publicado en 2002

Office Blood Pressure and Cardiovascular Disease: Pathophysiologic Implications for Diagnosis and Treatment

artículo científico publicado en 2017

Outcomes by gender in the African-American Heart Failure Trial.

artículo científico publicado en 2006

Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT.

artículo científico publicado en 2006

Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis

artículo científico publicado en 2018

Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study

artículo científico publicado en 2003

Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)

scientific article published on 01 September 2008

Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial

artículo científico publicado en 2014

Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.

artículo científico publicado en 2007

Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

artículo científico publicado en 2009

Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial

artículo científico publicado en 2009

Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of life

artículo científico publicado en 2006

Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome

artículo científico publicado en 2019

Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertension

artículo científico publicado en 2007

Screening for early detection of cardiovascular disease in asymptomatic individuals ⬇️

artículo científico publicado el 1 de octubre de 2003

Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials

artículo científico publicado en 2011

Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.

artículo científico publicado en 2010

Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data

artículo científico publicado en 2004

Signs and symptoms in chronic heart failure: relevance of clinical trial results to point of care-data from Val-HeFT.

artículo científico publicado en 2005

Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT

scientific article published on 17 October 2006

Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial

artículo científico publicado en 2003

Task force 2: Investigator participation in clinical research

artículo científico publicado en 2004

The African-American Heart Failure Trial: background, rationale and significance.

artículo científico publicado en 2002

The Problem With Cardiovascular Disease Prevention Guidelines ⬇️

artículo científico publicado el 1 de diciembre de 2012

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.

artículo científico publicado en 2004

The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT).

artículo científico publicado en 2006

Time to foster a rational approach to preventing cardiovascular morbid events

artículo científico publicado en 2008

Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes

article by Franco Cosmi et al published 28 February 2018 in European Journal of Heart Failure

Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?

artículo científico publicado en 2008

Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy

artículo científico publicado en 2004

Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study

artículo científico publicado en 2002

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

artículo científico publicado en 2005

Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observations

artículo científico publicado en 2011

Ventricular remodeling in heart failure: a credible surrogate endpoint ⬇️

artículo científico publicado el 1 de octubre de 2003

sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T

artículo científico publicado en 2018

Lista de obras de

Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) ⬇️

African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology

Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial.

Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.

Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice

Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment

Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials

Atrial fibrillation and mortality in African American patients with heart failure: Results from the African American Heart Failure Trial (A-HeFT) ⬇️

Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.

Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study

Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial.

C-reactive protein in heart failure: prognostic value and the effect of valsartan

Calculated plasma volume status and prognosis in chronic heart failure.

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T

Clinical and analytical considerations in the study of health status in device trials for heart failure

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

Contributors

Definition, classification, and staging of the adult cardiomyopathies: a proposal for revision.

Determinants of radial artery pulse wave analysis in asymptomatic individuals

Digoxin Use and Heart Failure Outcomes: Results from the Valsartan Heart Failure Trial (Val‐HeFT) ⬇️

Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data

EARTH: Endothelin A Receptor Antagonist Trial in Heart Failure

Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial

Early cardiovascular structural and functional abnormalities as a guide to future morbid events

Effect of Fixed-Dose Combined Isosorbide Dinitrate/Hydralazine in Elderly Patients in the African-American Heart Failure Trial ⬇️

Effect of Valsartan on hospitalization: results from Val-HeFT.

Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial

Effect of nebivolol or atenolol vs. placebo on cardiovascular health in subjects with borderline blood pressure: the EVIDENCE study.

Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.

Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial

Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial

Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT).

Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial

Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial

From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report

G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.

Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.

Heart Failure With Recovered Ejection Fraction in African Americans: Results From the African-American Heart Failure Trial.

High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure

Identifying early cardiovascular disease to target candidates for treatment

Incremental prognostic value of changes in B-type natriuretic peptide in heart failure

Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial

Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study

Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.

Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox

Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial

Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials

Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).

Nitric oxide's role in heart failure: pathophysiology and treatment. Introduction

Nuggets, pearls, and vignettes of master heart failure clinicians. Part 4--treatment

Office Blood Pressure and Cardiovascular Disease: Pathophysiologic Implications for Diagnosis and Treatment

Outcomes by gender in the African-American Heart Failure Trial.

Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT.

Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis

Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study

Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)

Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial

Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.

Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial

Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of life

Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome

Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertension

Screening for early detection of cardiovascular disease in asymptomatic individuals ⬇️

Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials

Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.

Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data

Signs and symptoms in chronic heart failure: relevance of clinical trial results to point of care-data from Val-HeFT.

Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT

Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial

Task force 2: Investigator participation in clinical research